Arbovirus Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The global arbovirus testing market size in 2026 is estimated at USD 0.96 billion, growing from 2025 value of USD 0.91 billion with 2031 projections showing USD 1.28 billion, growing at 5.84% CAGR over 2026-2031. This report is Segmented by Test Type (ELISA/MAC-ELISA, RT-PCR/QPCR, Isothermal, Rapid Antigen, Others), End User (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Arbovirus Testing Market Trends and Insights

Escalating Global Outbreaks of Dengue, Zika & Chikungunya

Record dengue notifications climbed to 13.7 million cases and 8,100 deaths across the Americas in 2024, a 260% leap over 2023 levels, pushing health-care systems toward molecular assays that enable serotype-specific management. Serological limitations during poly-virus circulation have prompted laboratories to upgrade to multiplex RT-PCR tools capable of distinguishing up to 32 arboviruses per run. Climate-related vector migration has driven local transmission in 15 previously unaffected countries, forcing non-endemic markets to stockpile diagnostic kits for front-line screening00298-9/fulltext). Novel reassortant Oropouche strains have also emerged, spurring demand for broad-spectrum detection panels. Economic modelling shows dengue now costs USD 4.1 billion annually, making early detection programs financially imperative.

Technological Advances in ELISA & RT-PCR Platforms

Next-generation ELISA readers use AI to cut indeterminate rates, lifting diagnostic accuracy to 99.6% for dengue serotype differentiation. Synthetic-biology-defined primers and CRISPR guard bands allow single-tube RT-PCR to concurrently detect 32 arboviruses without cross-reactivity penalties. Machine-learning analytics reduce false positives by 22% via amplification-curve pattern recognition. Extraction-free workflows shorten turnaround from four hours to under 65 minutes, a benefit proven during 2024 field pilots. Automation has freed skilled staff for confirmatory tasks, bolstering surge capacity during seasonal peaks.

Cross-Reactivity Complicating Regulatory Approvals

Antigenic overlap among flaviviruses forces assay makers to validate against 18-virus panels, extending average approval timelines to 32 months in 2024. Multiplex assays risk performance compromise if any target shows cross-talk, prompting regulators to request geographically diverse clinical datasets that inflate trial budgets. PRNT remains the gold standard but is impractical for routine labs due to seven-day incubation, leaving a validation gap for rapid formats. Fifteen new arboviral variants identified in 2024 required additional verification cycles, resetting launch calendars. This barrier advantages large incumbents with deeper pockets and seasoned regulatory teams.

Other drivers and restraints analyzed in the detailed report include:

• Rapid-Test Adoption Across LMIC Primary-Care Settings
• Government-Funded Vector-Surveillance Programs (Genomics-Enabled)
• Post-COVID Budget Diversion Away from Arbovirus Diagnostics

Segment Analysis

ELISA maintained the largest foothold with 41.98% of arbovirus testing market share in 2025, underscoring its entrenched role in population-level screening. The segment continues to benefit from low per-test costs and simple instrumentation, yet growing demand for rapid, decentralised decisions is catalysing a shift toward isothermal technologies. Isothermal platforms are forecast to register a 6.03% CAGR and are already live in more than 650 Asia-Pacific primary centres, offering 70% cheaper operations than conventional PCR without sacrificing sensitivity.

Rapid antigen devices remain the smallest slice but have achieved 99.1% specificity for dengue NS1, improving early-phase case detection. Hybrid cartridge designs now merge immunoassay capture with isothermal amplification, blurring historical boundaries and threatening ELISA primacy. CRISPR-guided detection paired with recombinase polymerase amplification is moving through eight clinical trials and could reconfigure the arbovirus testing market once commercialised.

Complete Report Scope:

• By Test Type (Value)
  • ELISA / MAC-ELISA
  • RT-PCR / qPCR
  • Isothermal
  • Rapid Antigen
  • Others
• By End User (Value)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America retained a 35.85% revenue lead in 2025 thanks to CDC-backed lab-capacity grants and FDA guidance that shortens review cycles for emerging-pathogen assays. Aedes aegypti has established breeding in 18 US states, up from 15 in 2023, extending the diagnostic catchment and driving new municipal procurements. Canada and Mexico co-fund cross-border incident platforms under the USD 145 million North American Health Security Partnership, harmonising reagent demand across the bloc.

Asia-Pacific will post the steepest trajectory at 7.42% CAGR through 2031 as urbanisation and warming climates expand mosquito habitats. India’s National Vector-Borne Disease Control Programme dedicated USD 580 million to diagnostic infrastructure in 2024, while China advanced USD 4.1 billion in infectious-disease testing funds, 18% earmarked for arboviruses. ASEAN states invested USD 820 million to align with WHO IHR standards, and venture financing in regional med-tech exceeded USD 3.6 billion. Vector-competence studies warn that 14 more countries could sustain dengue transmission by 2030, underscoring the region’s diagnostic urgency.

Europe shows stable growth, propelled by travel medicine and autochthonous clusters in France, Italy, Spain, and Croatia. The EU’s Enhanced Arbovirus Surveillance Network pooled EUR 105 million for unified diagnostics in 2024, simplifying market entry for kit makers. Southern and Central regions now document established Aedes albopictus populations, widening routine-testing geography. EMA regulatory harmonisation continues to reduce multi-country approval costs, providing a predictable arena for innovation roll-outs.

List of Companies Covered in this Report:

• Abbott Laboratories
• Roche
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• DiaSorin
• Siemens Healthineers
• QIAGEN
• Quest Diagnostics
• Cepheid (Danaher)
• Beckton Dickinson
• BioMérieux
• Euroimmun (Revvity)
• QuidelOrtho
• Altona Diagnostics
• Fast Track Diagnostics
• InBios International
• Creative Diagnostics
• Microbix Biosystems
• Orasure Technologies
• Tetracore

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support